[1]
|
吴文铭,陈洁,白春梅,等. 中国胰腺神经内分泌肿瘤诊疗指南(2020)[J]. 协和医学杂志,2021,12(4):460-480.
|
[2]
|
Raj N,Reidy-Lagunes D. Systemic therapies for advanced pancreatic neuroendocrine tumors[J]. Hematol Oncol Clin North Am,2016,30(1):119-133. doi: 10.1016/j.hoc.2015.09.005
|
[3]
|
Falconi M,Eriksson B,Kaltsas G,et al. ENETS Consensus Guidelines Update for the management of patients with functional pancreatic neuroendocrine tumors and non-functional pancreatic neuroendocrine tumors[J]. Neuroendocrinology,2016,103(2):153-171. doi: 10.1159/000443171
|
[4]
|
楼文晖,刘颖斌,梁廷波,等. 胰腺术后外科常见并发症诊治及预防的专家共识(2017)[J]. 协和医学杂志,2017,8(Z1):139-146.
|
[5]
|
宗志勇,朱仕超. 术后肺炎预防和控制专家共识[J]. 中华临床感染病杂志,2018,11(1):11-19.
|
[6]
|
Zhang I Y,Zhao J,Fernandez-Del Castillo C,et al. Operative versus nonoperative management of nonfunctioning pancreatic neuroendocrine tumors[J]. J Gastrointest Surg,2016,20(2):277-283. doi: 10.1007/s11605-015-3043-5
|
[7]
|
王喆,张磊,许雪峰. 胰腺神经内分泌肿瘤生物标记物研究进展[J]. 中国实用外科杂志,2022,42(10):1189-1193.
|
[8]
|
Lo G C,Kambadkone A. MR imaging of pancreatic neuroendocrine tumors[J]. Magn Reson Imaging Clin N Am,2018,26(3):391-403. doi: 10.1016/j.mric.2018.03.010
|
[9]
|
Yano M,Shetty A S,Williams G A,et al. Qualitative imaging features of pancreatic neuroendocrine neoplasms predict histopathologic characteristics including tumor grade and patient outcome[J]. Abdom Radiol (NY),2022,47(12):3971-3985. doi: 10.1007/s00261-022-03430-7
|
[10]
|
张轩豪,孟国梁. 胰腺神经内分泌肿瘤临床诊疗策略解析[J]. 现代医学与健康研究电子杂志,2023,7(1):134-138.
|
[11]
|
Lopez-Aguiar A G,Zaidi M Y,Beal E W,et al. Defining the role of lymphadenectomy for pancreatic neuroendocrine tumors: An eight-institution study of 695 patients from the US neuroendocrine tumor study group[J]. Ann Surg Oncol,2019,26(8):2517-2524. doi: 10.1245/s10434-019-07367-y
|
[12]
|
Zhang Z,Wang F,Li Z,et al. Value of lymphadenectomy in patients with surgically resected pancreatic neuroendocrine tumors[J]. BMC Surg,2022,22(1):160. doi: 10.1186/s12893-022-01595-y
|
[13]
|
Wang W Q,Zhang W H,Gao H L,et al. A novel risk factor panel predicts early recurrence in resected pancreatic neuroendocrine tumors[J]. J Gastroenterol,2021,56(4):395-405. doi: 10.1007/s00535-021-01777-0
|
[14]
|
Yoshida T,Hijioka S,Hosoda W,et al. Surgery for pancreatic neuroendocrine tumor G3 and carcinoma G3 should be considered separately[J]. Ann Surg Oncol,2019,26(5):1385-1393. doi: 10.1245/s10434-019-07252-8
|
[15]
|
Feng T,Lv W,Yuan M,et al. Surgical resection of the primary tumor leads to prolonged survival in metastatic pancreatic neuroendocrine carcinoma[J]. World J Surg Oncol,2019,17(1):54. doi: 10.1186/s12957-019-1597-5
|
[16]
|
Perysinakis I,Aggeli C,Kaltsas G,et al. Neoadjuvant therapy for advanced pancreatic neuroendocrine tumors: an emerging treatment modality?[J]. Hormones (Athens),2016,15(1):15-22. doi: 10.1007/BF03401399
|
[17]
|
韩序,楼文晖. 胰腺神经内分泌肿瘤的外科决策[J]. 肝胆外科杂志,2021,29(3):168-170.
|